MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-13-2025
Venus Concept Cost of Revenue 2011-2026 | VERO
Cost of Revenue is a financial metric that reflects all direct costs associated with the production of goods or the provision of services that directly led to revenue during the reporting period. It is the total amount of expenses incurred by the company to deliver its products or services, including both production costs and related expenses necessary for delivery or customer support.What is included in the cost of revenue
| Cost Category | Examples |
|---|---|
| Production Costs | Materials, wages of production staff, depreciation of equipment |
| Service and Support | Customer service, user support, technical assistance |
| Delivery and Logistics | Packaging, delivery of goods to customers |
| Hosting and Infrastructure | Servers, cloud platforms (especially for IT and SaaS companies) |
| Content and Licenses | License purchases, production royalties (e.g., in streaming services) |
Importance of the Metric
- Helps to understand how costly the revenue-generating process is.
- A high cost of revenue may indicate:
Poor cost control
Low operational efficiency - A low cost of revenue combined with high revenue indicates high profitability and business competitiveness.
Annual Cost of Revenue Venus Concept
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 20.5 M | 24.2 M | 33.5 M | 31.5 M | 26.6 M | 33.8 M | 23.3 M | 12.2 M | 10.4 M | 12.5 M | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 33.8 M | 10.4 M | 22.8 M |
Quarterly Cost of Revenue Venus Concept
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 4.96 M | 6.26 M | 4.89 M | - | 5.09 M | 4.73 M | 5.83 M | - | 5.43 M | 5.86 M | 6.83 M | - | 8.17 M | 8.22 M | 8.64 M | - | 7.26 M | 7.11 M | 7.36 M | - | 7.18 M | 5.1 M | 5.23 M | - | 7.39 M | 7.74 M | 6.52 M | - | 2.66 M | 2.51 M | 3.18 M | - | 2.47 M | 3.49 M | 3.09 M | - | 2.4 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 8.64 M | 2.4 M | 5.56 M |
Cost of Revenue of other stocks in the Medical devices industry
| Issuer | Cost of Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
AdaptHealth Corp.
AHCO
|
2.64 B | $ 13.11 | 0.23 % | $ 1.77 B |  USA |
 |
BIOLASE
BIOL
|
32.4 M | - | -13.19 % | $ 166 K | USA |
 |
Allied Healthcare Products
AHPI
|
24.5 M | - | 3.58 % | $ 2.21 M | USA |
 |
Eargo
EAR
|
23 M | - | - | $ 10.2 M | USA |
 |
Apollo Endosurgery
APEN
|
34.4 M | - | - | $ 475 M | USA |
 |
Second Sight Medical Products
EYES
|
11.4 M | - | -0.97 % | $ 54.4 M | USA |
 |
Electromed
ELMD
|
14 M | $ 25.71 | 2.43 % | $ 217 M | USA |
 |
Avinger
AVGR
|
5.65 M | - | -20.74 % | $ 369 K | USA |
 |
Axonics Modulation Technologies
AXNX
|
76 M | - | - | $ 3.31 B | USA |
 |
EDAP TMS S.A.
EDAP
|
37.6 M | $ 3.32 | 0.3 % | $ 124 M |  France |
 |
Aziyo Biologics
AZYO
|
5.7 M | - | 1.37 % | $ 20.5 M | USA |
 |
BioSig Technologies
BSGM
|
57 K | - | 37.08 % | $ 85.7 M | USA |
 |
Conformis
CFMS
|
38.8 M | - | - | $ 16.4 M | USA |
 |
ClearPoint Neuro
CLPT
|
14.3 M | $ 11.18 | 8.12 % | $ 317 M | USA |
 |
Helius Medical Technologies
HSDT
|
583 K | $ 2.04 | 3.03 % | $ 1.24 M | USA |
 |
Cardiovascular Systems
CSII
|
63.4 M | - | 0.15 % | $ 844 M | USA |
 |
Cytosorbents Corporation
CTSO
|
10.6 M | $ 0.61 | -4.04 % | $ 38 M | USA |
 |
Inspire Medical Systems
INSP
|
133 M | $ 56.14 | 5.11 % | $ 1.65 B | USA |
 |
Invacare Corporation
IVC
|
566 M | - | - | $ 24.7 M | USA |
 |
IRIDEX Corporation
IRIX
|
33.4 M | $ 1.03 | - | $ 17.4 M | USA |
 |
Dynatronics Corporation
DYNT
|
21.4 M | - | 14.99 % | $ 929 K | USA |
 |
Neovasc
NVCN
|
556 K | - | - | $ 111 M |  Canada |
 |
LivaNova PLC
LIVN
|
448 M | $ 60.1 | 2.0 % | $ 3.28 B |  Britain |
 |
OrthoPediatrics Corp.
KIDS
|
63.7 M | $ 15.06 | 2.87 % | $ 353 M | USA |
 |
Butterfly Network
BFLY
|
33.2 M | $ 4.79 | -2.64 % | $ 1.01 B | USA |
 |
GBS
GBS
|
1.81 M | - | -0.57 % | $ 7.12 M | USA |
 |
Globus Medical
GMED
|
958 M | $ 90.18 | 2.72 % | $ 12.2 B | USA |
 |
Delcath Systems
DCTH
|
11.8 M | $ 10.38 | 1.67 % | $ 372 M | USA |
 |
NanoVibronix
NAOV
|
2.4 M | - | - | $ 1.08 M | USA |
 |
CONMED Corporation
CNMD
|
624 M | $ 36.66 | 1.95 % | $ 1.14 B | USA |
 |
Integer Holdings Corporation
ITGR
|
1.35 B | $ 88.51 | 5.78 % | $ 3.07 B | USA |
 |
Edwards Lifesciences Corporation
EW
|
1.33 B | $ 83.5 | 2.81 % | $ 48.8 B | USA |
 |
LENSAR
LNSR
|
31.3 M | $ 5.23 | -2.97 % | $ 62.5 M | USA |
 |
Pulmonx Corporation
LUNG
|
23.4 M | $ 1.28 | 6.67 % | $ 52.1 M | USA |
 |
MiMedx Group
MDXG
|
73 M | $ 3.36 | 8.91 % | $ 497 M | USA |
 |
Myomo
MYO
|
14 M | $ 0.86 | 8.54 % | $ 36 M | USA |
 |
Cutera
CUTR
|
171 M | - | -10.19 % | $ 1.99 M | USA |
 |
NuVasive
NUVA
|
337 M | - | - | $ 2.07 B | USA |
 |
Nevro Corp.
NVRO
|
139 M | - | - | $ 217 M | USA |
 |
Natus Medical Incorporated
NTUS
|
197 M | - | 1.94 % | $ 1.05 B | USA |